… larger proportion of HIV-infected, treatment-naive persons as harboring drug-resistant viral
variants. Among participants who initiated treatment with the NNRTI strategy, the risk of VF …

… Antiretroviral treatment histories were obtained by chart review and correlated with drug-…
antiretrovirals in 17 of 22 subjects (77%). When correlated with subjects' antiretroviral treatment …

… antiretroviral treatment. The main causes for the emergence of drug-resistant HIV-1 variants
include suboptimum treatment … in an increased transmission of these viral variants. The pre-…

… Of note, 70% of subjects with minority Y181C variants achieved long-term viral suppression.
… -resistant variants significantly increased the risk of virologic failure of initial antiretroviral …

… viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly
impact treatment … HIV-1 variants, adherence, and risk of antiretroviral treatment failure. …

… the prevalence of R5 and X4 variants among Chilean patients under antiretroviral therapy
and virological failure and investigate variables such as plasma viral load (pVL) and CD4 cell …

… HBV variants and genetic patterns of lamivudine resistant HBV strains in a patient co-infected
with HIV-1 at different periods of an antiretroviral treatment with and without lamivudine. …

… the basis of: long-term viral suppression; treatment with nelfinavir (1250 mg twice daily) or
efavirenz (600 mg per day); antiretroviral treatment that suppressed viral load to less than 400 …

… type 1 (HIV-1) drug resistance is an important threat to the overall success of antiretroviral …
virological failure (defined as detectable viral load after 6 months of treatment); thus, our data …

… levels of virus variants with 1–3 drug-resistance mutations; 2% of them carried viruses resistant
… one additional minority drug-resistant variant, often a viral variant that was resistant to a …